首页    期刊浏览 2024年11月06日 星期三
登录注册

文章基本信息

  • 标题:CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin
  • 本地全文:下载
  • 作者:Simone Di Franco ; Barbara Parrino ; Miriam Gaggianesi
  • 期刊名称:iScience
  • 印刷版ISSN:2589-0042
  • 出版年度:2021
  • 卷号:24
  • 期号:6
  • 页码:1-18
  • DOI:10.1016/j.isci.2021.102664
  • 语种:English
  • 出版社:Elsevier
  • 摘要:SummaryLimited therapeutic options are available for advanced colorectal cancer (CRC). Herein, we report that exposure to a neo-synthetic bis(indolyl)thiazole alkaloid analog, nortopsentin 234 (NORA234), leads to an initial reduction of proliferative and clonogenic potential of CRC sphere cells (CR-CSphCs), followed by an adaptive response selecting the CR-CSphC-resistant compartment. Cells spared by the treatment with NORA234 express high levels of CD44v6, associated with a constitutive activation of Wnt pathway. In CR-CSphC-based organoids, NORA234 causes a genotoxic stress paralleled by G2-M cell cycle arrest and activation of CHK1, driving the DNA damage repair of CR-CSphCs, regardless of the mutational background, microsatellite stability, and consensus molecular subtype. Synergistic combination of NORA234 and CHK1 (rabusertib) targeting is synthetic lethal inducing death of both CD44v6-negative and CD44v6-positive CRC stem cell fractions, aside from Wnt pathway activity. These data could provide a rational basis to develop an effective strategy for the treatment of patients with CRC.Graphical abstractDisplay OmittedHighlights•CR-CSCs acquire a long-term resistance to the NORA234 treatment•Replicative and genotoxic stress induces the activation of CHK1•Adaptive response to NORA234 is associated with high expression levels of CHK1•NORA234 together with targeting of CHK1 leads to depletion of CR-CSC compartmentCancer; Cell biology; Drugs; Molecular physiology
国家哲学社会科学文献中心版权所有